Unicycive Therapeutics, Inc. corrected the expiration dates in previously filed exhibits and reported an exchange agreement on March 13, 2024, where investors exchanged 43,649,000 shares of Series A-2 Preferred Stock for 21,388.01 shares of new Series A-2 Prime Preferred Stock.